In a trans‑male patient on testosterone therapy who presents with vaginal itching, what are the possible causes and how should it be evaluated and treated?

Vaginal Itching in FtM Patients on Testosterone

Vaginal itching in transgender men on testosterone therapy is most commonly caused by testosterone-induced vaginal atrophy (similar to menopause), which leads to loss of protective Lactobacillus species, increased vaginal pH, and bacterial dysbiosis—treat with topical vaginal estrogen as first-line therapy.

Understanding the Mechanism

Testosterone therapy fundamentally alters the vaginal microbiome in transgender men. Research demonstrates that 89% of transgender men develop vaginal dysbiosis after testosterone initiation, with 56% developing bacterial vaginosis 1. The vaginal microbiome shifts from Lactobacillus-dominant flora to increased intestinal bacteria including Campylobacter, Anaerococcus, Dialister, and Prevotella 2. This occurs because testosterone suppresses local estrogen, eliminating the acidic, Lactobacillus-rich environment that protects against infection 3.

The timeline matters: most cases of bacterial vaginosis develop between days 20-40 after testosterone initiation 1, though chronic atrophic changes persist long-term.

Differential Diagnosis to Evaluate

When a transgender man on testosterone presents with vaginal itching, systematically assess:

• Vaginal atrophy (most common): Look for vaginal dryness, pH >5, loss of rugae, pale/thin vaginal epithelium, absence of discharge
• Bacterial vaginosis: Thin gray-white discharge, fishy odor, pH >4.5, clue cells on wet mount
• Candidiasis: Thick white discharge, normal pH <4.5, pseudohyphae on KOH prep
• Contact dermatitis: From testosterone gel transfer, binders, or new products
• Sexually transmitted infections: Obtain testing for gonorrhea, chlamydia, trichomonas based on sexual history

Key diagnostic steps:

• Vaginal pH measurement (>5 suggests atrophy or BV)
• Wet mount microscopy (assess for clue cells, yeast, trichomonads, lactobacilli)
• Nugent score if available (≥7 confirms BV)
• Sexual history and recent product exposures

Treatment Algorithm

First-Line: Topical Vaginal Estrogen

Prescribe low-dose vaginal estrogen cream (0.5-1g conjugated estrogens or 10mcg estradiol) inserted vaginally 2-3 times weekly. This directly addresses the root cause—estrogen deficiency in vaginal tissue—without significantly affecting systemic testosterone levels or masculinization 4. Studies show vaginal estrogen restores Lactobacillus colonization, normalizes pH, and improves vaginal health scores 4.

Critically, intravaginal estrogen use is positively associated with Lactobacillus presence in transgender men (p=0.045) 3, reversing the dysbiotic state that causes symptoms.

If Bacterial Vaginosis is Confirmed

Add metronidazole 500mg PO BID for 7 days or metronidazole 0.75% gel intravaginally daily for 5 days alongside vaginal estrogen. The estrogen prevents recurrence by restoring protective flora.

If Candidiasis is Present

Treat with fluconazole 150mg PO once or topical azole (miconazole/clotrimazole) for 3-7 days, then initiate vaginal estrogen for prevention.

Alternative: Topical Testosterone

While counterintuitive, topical testosterone 0.04g daily has shown efficacy for vulvar symptoms in postmenopausal women 5. However, this carries significant risk: serum testosterone levels increased in all patients and exceeded normal range in 80%, with 40% developing hyperandrogenism (clitoral enlargement, voice changes) after just 4 weeks 5. This is NOT recommended for transgender men already on systemic testosterone due to compounding virilization risk.

Critical Monitoring Points

Following the Endocrine Society guidelines for testosterone monitoring 6:

• Evaluate patients at 3-6 months after testosterone initiation, then annually for adverse effects 6
• Check hematocrit at baseline, 3-6 months, then annually—stop if >54% 6
• Monitor testosterone levels at 3-6 months to maintain mid-normal male range (320-1000 ng/dL) 7
• Assess formulation-specific adverse effects at each visit 6

For vaginal symptoms specifically:

• Reassess vaginal pH and symptoms 4-6 weeks after starting vaginal estrogen
• If no improvement, reconsider diagnosis (STI testing, dermatology referral for lichen sclerosus)
• Continue vaginal estrogen long-term as testosterone-induced atrophy persists

Common Pitfalls to Avoid

1. Don't assume all vaginal symptoms are infections: The majority (>60%) of transgender men experience vulvovaginal symptoms, primarily from atrophy 8

2. Don't hesitate to prescribe vaginal estrogen: Providers often worry about "reversing" masculinization, but topical vaginal estrogen has minimal systemic absorption and doesn't interfere with gender-affirming therapy 4

3. Don't use systemic estrogen: Only topical vaginal estrogen is appropriate—systemic estrogen would counteract testosterone effects

4. Don't overlook sexual activity as a trigger: Sexual activity influences dysbiosis development 1—counsel on adequate lubrication and consider pre-activity vaginal estrogen application

5. Don't use topical testosterone on genitals: Risk of systemic absorption and hyperandrogenism is unacceptably high in patients already on testosterone 5

The evidence strongly supports that vaginal estrogen is safe, effective, and should be offered proactively to transgender men experiencing vaginal symptoms on testosterone therapy, as it addresses the underlying pathophysiology without compromising gender-affirming treatment goals.